Targeting the RAF–MEK–ERK pathway with MEK inhibitors, enhances growth inhibition and apoptosis in OCa harboring KRAS or BRAF mutations suggesting their dependence on RAS–RAF–MEK–ERK signaling for survival [5]. The gene discussed is MAP2K7; the disease is oculocutaneous albinism.